Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment.
Anticancer Res
; 37(3): 1305-1311, 2017 03.
Article
en En
| MEDLINE
| ID: mdl-28314296
ABSTRACT
AIM:
To evaluate modifications of perfusional parameters assessed by perfusion computed tomography (P-CT) of liver metastases (LM) from pancreatic neuroendocrine tumors (PanNETs) during everolimus treatment. PATIENTS ANDMETHODS:
All patients with LMs from G1-2 PanNETs undergoing everolimus treatment between January 2013 and January 2015 were prospectively evaluated with P-CT at baseline, and after 2 and 4 months of therapy. Size, perfusion, blood volume (BV), peak enhancement intensity (PEI) and time to peak for each lesion were calculated.RESULTS:
A total of 33 LMs in nine patients with G1-2 PanNETs were prospectively evaluated 23/33 (69.7%) were responders, 10/33 (30.3%) were non-responders. Among perfusional parameters, only numerical peak enhancement intensity values significantly differed between the two groups at baseline (p=0.043). BV increase was the most significant perfusional modification identifying responding lesions, even at an early stage of treatment, with a high positive predictive value (89.47%).CONCLUSION:
P-CT seems to be useful for prediction of response to everolimus of LMs from PanNETs.Palabras clave
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Tomografía Computarizada por Rayos X
/
Tumores Neuroendocrinos
/
Everolimus
/
Neoplasias Hepáticas
/
Antineoplásicos
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Anticancer Res
Año:
2017
Tipo del documento:
Article
País de afiliación:
Italia